14 completed, 5 recruiting, 5 terminated, 2 not yet recruiting. 14 Phase 2, 10 Phase 1, 8 Phase 3, 2 Not applicable, 1 Phase 4.
Follow Ichthyosiform Erythroderma, Congenital: new trials by email Literature Review of Ichthyosiform Erythroderma, Congenital trials Research Report on Ichthyosiform Erythroderma, Congenital
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Study of Skin and Gut Microbiome in a Skin Condition Involving Skin Barrier Impairment and Allergic Symptoms: Netherton Syndrome Superficial skin swabs, Stool samples, Saliva samples - Netherton Syndrome | Recruiting | Assistance Publique - Hôpitaux de Paris | 30 | 2026-05-26 | 2026-06-30 | |
| Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD) blood sampling - Sezary Syndrome, Ichthyosis, Lamellar | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2026-04-01 | 2026-03-17 | |
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003 - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 16 | 2026-03-19 | 2026-09-28 |
| Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 8 | 2025-10-06 | 2026-08-31 |
| Natural History of Netherton Syndrome Netherton Syndrome | Terminated | Boehringer Ingelheim | 4 | 2024-10-09 | 2026-06-24 | |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725 BCX17725, Placebo - Netherton Syndrome | Phase 1 | Recruiting | BioCryst Pharmaceuticals | 78 | 2024-09-26 | 2026-08-27 |
| Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome ATR12-351 - Netherton Syndrome | Phase 1 | Completed | Azitra Inc. | 6 | 2024-06-16 | 2026-07-29 |
| A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome DS-2325a, Placebo - Netherton Syndrome | Phase 1 / Phase 2 | Terminated | Daiichi Sankyo | 9 | 2023-09-28 | 2026-05-14 |
| A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | Boehringer Ingelheim | 43 | 2023-06-12 | 2026-03-12 |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome QRX003, 4% Lotion - Netherton Syndrome | Phase 2 / Phase 3 | Recruiting | Quoin Pharmaceuticals | 20 | 2023-03-14 | 2026-08-31 |
| Study of in Vivo and in Vitro Transcriptomic and Proteomic Signatures in Unhereditary Ichtyosis Biological samples, Skin biopsy - Autosomal Recessive Congenital Ichthyosis, Epidermolytic Ichthyosis | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 18 | 2022-12-07 | 2024-07-16 |
| A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 24 | 2022-11-08 | 2023-05-18 |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle - Netherton Syndrome | Phase 2 / Phase 3 | Active not recruiting | Quoin Pharmaceuticals | 30 | 2022-06-23 | 2026-03-16 |
| A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects DS-2325a, Placebo - Netherton Syndrome | Phase 1 | Completed | Daiichi Sankyo | 64 | 2022-06-20 | 2023-03-06 |
| A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome SXR1096 cream, Placebo cream - Netherton Syndrome | Phase 1 / Phase 2 | Completed | Sixera Pharma | 9 | 2021-12-07 | 2025-12-16 |
| Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children Secukinumab Injection, Ustekinumab Injection, Dupilumab Injection - Congenital Ichthyosis | Phase 4 | Unknown | National Medical Research Center for Children's Health, Russian Federation | 50 | 2021-03-01 | 2021-08-09 |
| A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome | Phase 2 / Phase 3 | Terminated | University Hospital, Toulouse | 10 | 2020-07-23 | 2026-09-21 |
| A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis | Phase 2 | Terminated | Mayne Pharma International Pty Ltd | 65 | 2019-05-01 | 2023-08-14 |
| Defining the Skin and Blood Biomarkers of Ichthyosis Ichthyosis, Netherton Syndrome | Enrolling by invitation | Northwestern University | 200 | 2018-01-31 | 2026-04-27 |
Showing 20 of 30. Sign in to see all of them.
Netherton Syndrome (22) · Ichthyosis, Lamellar (7) · Ichthyosis (5) · Hyperkeratosis, Epidermolytic (4) · Darier Disease (2) · Skin Diseases, Genetic (2) · Dermatitis, Atopic (1) · Dermatitis, Exfoliative (1) · Eczema (1) · Epidermal Nevus (1) · Ichthyosis Vulgaris (1) · Ichthyosis, X-Linked (1) · Keratoderma, Palmoplantar (1) · Keratosis (1)
Congenital Abnormalities (30) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (30) · Genetic Diseases, Inborn (30) · Infant, Newborn, Diseases (30) · Skin Abnormalities (30) · Skin and Connective Tissue Diseases (30) · Keratosis (29) · Skin Diseases (29) · Skin Diseases, Genetic (28) · Ichthyosis (25) · Abnormalities, Multiple (23) · Dermatitis (2) · Immune System Diseases (2) · Ectodermal Dysplasia (1)
Blood Specimen Collection (3) · secukinumab (2) · Adalimumab (1) · Biopsy (1) · Data Collection (1) · Erlotinib Hydrochloride (1) · Injections (1) · Ustekinumab (1) · WAS protein, human (1) · dupilumab (1) · liarozole (1) · pimecrolimus (1) · spesolimab (1) · trifarotene (1)
Assistance Publique - Hôpitaux de Paris (4) · Quoin Pharmaceuticals (4) · Daiichi Sankyo (3) · Northwestern University (3) · Boehringer Ingelheim (2) · Azitra Inc. (1) · BioCryst Pharmaceuticals (1) · Centre Hospitalier Universitaire de Nice (1) · Children's Hospital of Philadelphia (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Mayne Pharma International Pty Ltd (1) · National Cancer Institute (NCI) (1) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · National Medical Research Center for Children's Health, Russian Federation (1)
United States (18) · France (12) · Germany (5) · Netherlands (4) · United Kingdom (4) · Australia (3) · Italy (3) · Canada (2) · Israel (2) · Sweden (2) · Austria (1) · Belgium (1) · Bulgaria (1) · China (1) · Dominican Republic (1)
Tony Andrasfay (2) · Alain Hovnanian, MD, PhD (1) · Albert C Yan, MD (1) · Amy Paller (1) · Amy Paller, MD (1) · Chiaverini Christine, Dr (1) · Christine Bodemer, MD, PhD (1) · Emma Guttman-Yassky, MD, PhD (1) · Jemima Mellerio, Dr (1) · Keith A. Choate, MD (1) · Koen van Rossem, MD, PhD (1) · Maarten de Chateau, MD PhD (1)
PMID 11511292, PMID 11912510, PMID 12648223, PMID 14734878, PMID 15238912, PMID 16250204, PMID 18571597, PMID 18948357, PMID 19241467, PMID 20083693, PMID 24102348, PMID 24329107, PMID 34543653, PMID 35218370, PMID 40908106, PMID 9804339, PMID 9843209
2014 (1), 2025 (1)